UFC FIGHT PASS® to Be Made Available on VIDAA-Powered Hisense and Toshiba Smart TVs
4.6.2021 10:00:00 EEST | Business Wire | Press release
UFC®, the world’s premier mixed martial arts organization, and Hisense, the world-class technology company, today announced a distribution and marketing collaboration centered on UFC FIGHT PASS®, the world’s leading subscription streaming service for combat sports, which will be released on VIDAA-powered Hisense and Toshiba smart TVs.
Starting in August, UFC FIGHT PASS will be distributed on new select Hisense TVs as well as on Toshiba Smart TVs manufactured by Hisense that utilize the VIDAA smart platform, a Linux-based open smart TV operating system that is present on products in more than 120 countries around the world.
UFC FIGHT PASS provides subscribers with access to live UFC events; live local mixed martial arts and combat sports from around the world; original series and historical programming; and the world’s largest fight library, featuring more than 20,000 bouts from dozens of combats sports organizations, as well as every fight in UFC history.
As an official marketing partner of UFC, Hisense branding will be featured in the world-famous Octagon® at select UFC events for the remainder of 2021. In addition, Hisense will be the presenting partner of select UFC digital content distributed across UFC social media platforms in the United Kingdom, Ireland, Europe, and the Middle East.
“We are delighted to partner with Hisense and VIDAA to deliver the incredible combat sports content on UFC FIGHT PASS to more fans than ever before,” said Crowley Sullivan, Vice President and General Manager of UFC FIGHT PASS. “This collaboration is a win-win, as it will help us expand our global reach for FIGHT PASS, while exposing Hisense products to UFC’s fan base in key markets.”
“Partnering with UFC, the world leader in MMA, is a big step in bringing the best sports content to our VIDAA users. I believe that we can grow our businesses faster together, since VIDAA is present in almost every country in the world and UFC is becoming increasingly more popular outside the U.S. as well,” said Guy Edri, Executive Vice President for Business Development for VIDAA.
About UFC®
UFC® is the world’s premier mixed martial arts organization (MMA), with more than 625 million fans and 155 million social media followers. The organization produces more than 40 live events annually in some of the most prestigious arenas around the world, while broadcasting to approximately 900M TV households across more than 175 countries. UFC’s athlete roster features the world’s best MMA athletes representing more than 70 countries. The organization’s digital offerings include UFC FIGHT PASS®, one of the world’s leading streaming services for combat sports. UFC is owned by global entertainment, sports and content company Endeavor, and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com and follow UFC at Facebook.com/UFC, Twitter, Snapchat, Instagram and TikTok: @UFC.
About Hisense
Hisense currently has more than 90,000 employees worldwide, together with 16 industrial parks and 16 research and development centres, which comprise a multinational collaborative research and development system. Its business includes multimedia, home appliances, IT intelligent information systems and the modern service industry, while its products have been exported to over 160 countries and regions. According to an independent research and consultancy firm, Hisense remains the world’s fourth-largest TV maker in terms of unit shipments (per 2020 figures).
About VIDAA
VIDAA is a Linux-based open smart TV operating system. Established in 2014, it has - in just six years - become a strong global contender in the smart TV platform space. In 2020, VIDAA introduced a completely new and revamped user interface named 4.0, which puts users and their way of consuming content at the core of the design. The latest version of VIDAA - U5 was launched in May 2021. VIDAA is preinstalled on new Hisense TVs as well as Toshiba Smart TVs manufactured by Hisense. For more information, visit www.vidaa.com and follow VIDAA on Facebook.com/vidaatv, Twitter, and Instagram at @vidaatv.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210604005152/en/
Contact information
Press Contact for Hisense:
Lori Luo (Ogilvy PR Team)
Email: lori.luo@ogilvy.com / HisenseGlobal@ogilvy.com
Press Contact for UFC:
Niamh Moran
+44 7800 513 876
nmoran@ufc.com
Press Contact for VIDAA:
Jernej Smisl
+386 31 689 862
jernej.smisl@vidaa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom